• 1
    Lawrence WJR, Donegan WL, Natarajan N, et al. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987; 205: 349-359.
  • 2
    Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981; 47: 2392-2397.
  • 3
    Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of limb-sparing surgery plus radiation therapy compared with amputation and the role of adjuvant chemotherapy. Ann Surg. 1982; 196: 305-315.
  • 4
    Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996; 14: 859-868.
  • 5
    Rydholm A, Gustafson P, Rooser B, et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol. 1991; 10: 1757-1765.
  • 6
    Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999; 17: 3252-3259.
  • 7
    Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1991; 221: 1493-1499.
  • 8
    Delaney TF, Rosenberg D, Harmon DC, et al. Soft tissue sarcomas. In: PriceP, SikoraK, eds. Treatment of Cancer. 4th ed. London, UK: Arnold; 2002: 867-907.
  • 9
    Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985; 3: 353-366.
  • 10
    Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006; 24: 619-625.
  • 11
    Spiro IJ, Suit H, Gebhardt M, et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 1996; 15: 524. Abstract 168.
  • 12
    DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Biol Phys. 2003; 56: 1117-1127.
  • 13
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980: 163-178.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 15
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [editorial]. Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346.
  • 16
    Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br J Surg. 1995; 82: 1208-1212.
  • 17
    Fabrizio PL, Stafford SL, Pritchard DJ. Extremity soft-tissue sarcomas selectively treated with surgery alone. Int J Radiat Oncol Biol Phys. 2000; 48: 227-232.
  • 18
    Kim B, Chen YL, Goldberg SI, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Biol Phys. 2010; 77: 843-850.
  • 19
    Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16: 197-203.
  • 20
    O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomized trial. Lancet. 2002; 359: 2235-2241.
  • 21
    O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004; 22: 9007.
  • 22
    Davis A, O'Sullivan, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005; 75: 48-53.
  • 23
    Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996; 14: 869-877.
  • 24
    Edmonson JH, Petersen IA, Shives TC, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas. Cancer. 2002; 94: 786-792.
  • 25
    Nedea EA, Spiro IJ, Suit HD, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas [abstract]. Int J Radiat Oncol Biol Phys. 2006; 66( 3 suppl): S118.
  • 26
    Bramwell VHC. Controversies in surgical oncology: routine anthracycline-based adjuvant chemotherapy for stage III extremities soft tissue sarcoma. Ann Surg Oncol. 2007; 14: 1254-1256.
  • 27
    Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27 [abstract]. Breast Cancer Res Treat. 2005; 88: S16. Abstract 26.
  • 28
    Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003; 21: 1574-1580.
  • 29
    Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350: 1647-1654.
  • 30
    Pervaiz N, Cotterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113: 573-581.
  • 31
    Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009; 20: 425-430.
  • 32
    Le Cesne A, Van Glabbeke MV, Woll PJ, et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J Clin Oncol. 26;( suppl): 2008. Abstract 10525.
  • 33
    Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004; 240: 686-697.
  • 34
    Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105-113.
  • 35
    Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumors. Target Oncol. 2009; 4: 45-56.
  • 36
    Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009; 11: 307-313.
  • 37
    Lopez G, Liu J, Ren W, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009; 15: 3472-3483.